Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Biotech
Royalty signs off $2B to bankroll Revolution's RAS cancer drug
Revolution secured the funding infusion from Royalty in return for a slice of the profits if Revolution's lead cancer drug makes it to market.
James Waldron
Jun 24, 2025 9:00am
Nuvalent trots out strong pivotal data in FDA lung cancer push
Jun 24, 2025 6:30am
ASCO: Cullinan drug sees 35% ORR in pretreated NSCLC
May 22, 2025 5:00pm
Roche nets FDA breakthrough label for AI lung cancer CDx test
Apr 29, 2025 2:07pm
BeiGene drops TIGIT drug over poor phase 3 lung cancer prospects
Apr 3, 2025 8:05am
Apollomics sells Asia rights to c-MET inhibitor in $60M deal
Mar 31, 2025 9:44am
